Business Wire

ENVISION-ENERGY

3.5.2016 10:01:57 CEST | Business Wire | Press release

Share
Envision Energy to Acquire BazeField

Envision, one of the world’s leading renewable energy and technology companies, today announced the acquisition of Norway-based BazeField technology in a partnership that will drive both companies forward in the digital energy revolution.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160503005810/en/

The partnership with BazeField is a continuation of Envision’s commitment to cooperate with the best companies around the world to develop solutions to meet global energy and climate challenges, and enable the necessary transition to a low-carbon global economy.

“BazeField is at the cutting edge of renewable energy system management technology,” said Felix Zhang, Envision executive director. “The acquisition will provide the resources and support for BazeField to further develop its state-of-the-art technology, and provide better products and services to its global clients. The synergies and complementary technologies between Envision and BazeField will create a partnership that will drive forward growth and innovation for both companies.”

According to Zhang, the digital energy technology market is at an early stage of development, fragmented and geographically diverse. “At this stage of the market’s development, innovation and growth requires more partnerships and greater cooperation,” he said. “The new relationship between Envision and BazeField will play a key part in achieving those goals and pushing the market forward.”

BazeField will continue to operate independently under the agreement. “The independence of BazeField is important for the success of this partnership,” Zhang said. “With Bazefield operating independently, customers will have more choice and BazeField will have the autonomy it needs to continue its development efforts.”

“We decided we would need a partner to grow with,” said BazeField CEO Sigurd Juvik. “Envision is the right partner for us. The companies have a similar vision for smart energy technology and the partnership offers us the resources and industry insights that will accelerate our product development and entry into new market regions. We have confidence in our technology. Moving forward with Envision Energy is an endorsement of that, and a massive vote of confidence.”

Zhang pointed out that the world is rapidly moving to a future energy system that is completely different from today’s. “This energy future will rely on society and business being able to run an energy system in which digitalisation means greater control and improved efficiency at every juncture,” Zhang said. “Envision Energy and BazeField are at the forefront of this transition, using software to maximise the efficiency of every piece of hardware they help to operate. The global market is undergoing a fundamental paradigm shift and global cooperation is a must.”

After the acquisition is complete, customers will be able to use the same technology platforms they have chosen from Envision or BazeField, but with added innovation and potential. Juvik said, “The combination of BazeField and Envision Energy will accelerate investment in BazeField’s technology, increase both companies’ rate of growth and geographic expansion, and increase employment and investment in Norway and Europe, all of which will help us overcome the challenges we face today in energy and the environment.”

About Envision Energy

Envision Energy (www.envision-energy.com ) is one of the world's largest smart energy management companies and among the eight largest turbine companies in the world with more than 7.5 GW of Envision smart wind turbines in operation. Envision's Energy OS platform is used to manage more than 50 GW of renewable energy assets, including charging stations and energy consumption devices worldwide. Envision has regional offices across Asia, Europe, North and South America and has established global R&D and engineering centers in Denmark, Germany and the United States.

About BazeField

Baze Technology is a software company headquartered in Norway. It’s industry leading product, BazeField Wind, is a turbine independent Wind Farm Management System (WFMS) that provides tools for real-time monitoring, reporting, availability planning, stop and loss analysis and fact-based decision making. BazeField’s Wind Farm Management System includes turnkey interfaces such as: turbine SCADA, grid, met, forecasts, trading systems etc. It also includes a suite of monitoring, analysis and operations management applications, KPI's measurements and reports needed for support in O&M of wind farms.

Envision Energy/BazeField

Transaction Summary

Purpose of the deal

With the partnership with BazeField, Envision Energy continues to cooperate with the best companies around the world to develop solutions to meet the global energy and climate challenges.

Envision Energy

Founded: 2007

HQ: Registered in Hong Kong

Employees: More than 1,000 renewable energy and software development professionals working in 12 countries.

Market position in global renewables energy and technology market:

  • Second largest wind turbine company in China
  • A top-10 wind turbine technology provider in the world
  • Developed a leading lifecycle management system that features smart sensor networks and cloud-based IT infrastructure designed to create smart wind farms
  • Largest smart energy management company in the world, currently managing more than 50 million kilowatts of global alternative energy assets
  • Largest offshore turbine supplier in China
  • Current markets: China, UK, Mexico, Chile, Denmark (R&D), Germany (R&D), US (R&D, System Management)

Products/Services

Wind turbines and systems

Solar power software systems

Smart energy management technology

Many other digital energy solutions

Executives

Zhang Lei - Chief Executive Officer

Felix Zhang - Executive Director

Tim Naylor - Head of Software Sales in Europe

Tim Hertel - Head of Software Sales in North America

John Childs - Head of Turbine Business Development for Europe Middle East & Africa

Michael Friedrich - Chief System Engineer

Mathias Mier - Director of Technology & Quality

Markets

Envision in North America/South America – Aerodynamics R&D, global digital energy centre and innovation lab, Envision Ventures

Envision in Europe – 1 global innovation centres

Envision in APAC – Global manufacturing, R&D, international project CoE business operations and smart energy software R&D

BazeField

Founded: 2007 as a spin-off from CARDIAC AS

HQ: Porsgrunn, Norway

Products/Services

BazeField Wind is a turbine independent Wind Farm Management System (WFMS) that provides tools for real-time monitoring, reporting, availability planning, stop and loss analysis, and fact-based decision-making. Approximately 7 GW of installed wind power capacity are managed on a daily basis.

Executives

Sigurd J. Juvik – Chief Executive Officer

Tor-Egil Tinderholt – Chief Financial Officer/Chief Operating Officer

Thorstein Rinker – Vice President Business Development

John Båserud – Chief Technology Officer

Contact:

For Envision Energy:
UK
Stephanie Bailey, +44 (0) 208 618 2809
Press office
Stephanie.bailey@fhflondon.co.uk
or
Norway
Rune Mørck Wergeland, +47 913 88 914
Press office
rmw@wask.no
or
Brussels
Alexandria Hicks, +32 470 904 333
Press office
alexandria.hicks@fleishmaneurope.com
or
San Francisco
Yang Stratton, 650-564-5036
yang.stratton@envision-energy.com
or
Houston - Joe Brettell, +1713-513-9511
Press office
joe.brettell@fleishman.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye